REFERENCES
- Pridjian G, Puschett JB. Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002; 57(9):590–598.
- Libby G, Murphy DJ, McEwan NF, Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort. Diabetologia 2007; 50(3):523–530.
- Conrad KD. Animal models of preeclampsia: do they exist? Fetal Med Rev 1990; 2:7–8.
- Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on research on hypertension during pregnancy. Hypertens 2003; 41:437–445.
- Pridjian G, Puschett JB. Preeclampsia. Part II: experimental and genetic considerations. Obstet Gynecol Surv 2002; 57:619–640.
- Scott DE. Anemia in pregnancy. Obstet Gyn Ann 1972; 1:219–244.
- Puschett, JB. The role of excessive volume expansion in the pathogenesis of preeclampsia. Med Hypotheses 2006; 67:1125–1132.
- Ianosi-Irimie M, Vu HV, Whitbred JM, A rat model of preeclampsia. Clin Exp Hypertens 2005; 8:605–617.
- Vu HV, Ianosi-Irimie MR, Pridjian CA, Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005; 25:520–528.
- Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 2002; 269:2440–2448.
- Vu HV, Ianosi-Irimie M, Danchuk S, Resibufogenin corrects hypertension in a rat model of human preeclampsia. Exp Biol Med 2006; 231:215–220.
- Federosa OV, Lakatta EG, Bagrov AY. Endogenous Na, K pump ligands are differentially regulated during acute NaCl loading of Dahl rats. Circulation 2000; 102:3009–3014.
- Uddin MN, McLean LB, Hunter F, Vascular leak in a rat model of preeclampsia. Am J Nephrol 2009; 30:26–33.
- Fedorova OV, Doris PA, Bagrov AY. Endogenous marinobufagenin-like factor in acute plasma volume expansion. Clin Exper Hypertens 1998; 20(5–6):581–591.
- Gonick HC, Ding Y, Vaziri ND, Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens 1998; 20(5–6):617–627.
- Lopatin DA, Ailamazian EK, Dmitrieva RI, Circulating bufadienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17:117–1187.
- Uddin MN, Horvat D, Glaser SS, Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells. Placenta 2008; 29:266–273.
- LaMarca HL, Morris CA, Pettit GR, Marinobufagenin impairs first trimester cytotrophoblast differentiation. Placenta 2006; 27(9–10):984–988.
- Danchuk S, Sukhanov S, Horvat D, Effects of resibufogenin in experimental hypertension. Am J NephroI 2008; 28:8–13.
- Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997; 11(6):657–666.
- Melamed M, Castano E, Notides AC, Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol 1997; 11(12):1868–1878.
- Spitz IM. Progesterone receptor antagonists. Curr Opin Investig Drugs 2006; 7(10):882–890.
- Dvela M, Rosen H, Feldmann T, Diverse biological responses to different cardiotonic steroids. Pathophysiol 2007; 14:l59–166.
- Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs 2007; 7(3):173–189.
- Feldmann T, Glukmann V, Medvenev E, Role of endosomal Na+, K+-ATPase and cardiac steroids in the regulation of endocytosis. Am J Physiol Cell Physiol 2007; 293:885–896.